Market news

Exelixis (NasdaqGS: EXEL) said the FDA has extended its review of zanzalintinib plus atezolizumab for metastatic colorectal cancer. The agency lengthened the decision timeline after Exelixis submitted a major amendment with updated safety and efficacy data. The extended FDA review tied to new zanzalintinib safety and efficacy information only captures part of what matters today. Check out 4 other big wins that Exelixis investors should know about. To put this regulatory update in context,...

Exelixis (NASDAQ:EXEL) President and CEO Michael Morrissey said the company is focused on expanding its oncology franchises through internal development, selective business development and potential collaborations, while preparing for a planned launch of zanzalintinib in metastatic colorectal cancer

Exelixis, Inc. (NASDAQ:EXEL) disclosed in a September 11 filing that the FDA had extended the review of zanzalintinib by three months, setting a new target action date of March 3, 2027. The September 10 notification followed an FDA request for updated safety and efficacy information. The submitted data were classified as a major amendment. The […]

Exelixis (NASDAQ:EXEL) executives outlined plans to continue expanding the CABOMETYX franchise while preparing for a potential launch of zanzalintinib, or zanza, in colorectal cancer later this year. Speaking at a Wells biotech session, Chief Financial Officer Chris Senner said the company is worki

The FDA extended its review of Exelixis' zanzalintinib by three months, but no new clinical failure or safety signal was disclosed. Read why EXEL stock is a Buy.

Detailed price information for Heico Corp (HEI-N) from The Globe and Mail including charting and trades.

Exelixis stock dropped out of a buy zone Friday after the FDA delayed the potential approval of its new colon cancer combo.

Food and Drug ‌Administration has extended the ‌review of Exelixis' experimental colorectal ​cancer drug combination by three months, the company said in a filing ‌on Friday. The ⁠regulator will now make its decision by ⁠March 3, 2027.

Exelixis (EXEL) said Friday that the US Food and Drug Administration extended the review period for

SAN DIEGO and SUZHOU, China, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced the achievement of a milestone in its ongoing collaboration and license agreement with Exelixis, Inc. (“Exelixis”). The milestone achievement is related to a preclinical milestone event for XB404 and resulted in a $2.0 million milestone payment

Exelixis is Friday's IBD Stock Of The Day. Shares have recovered from a post June-quarter drop and are trading in a buy zone.

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Cancer treatment name Exelixis is attempting to clear a flat base with a pivot at 57.57 after second-quarter earnings.

Exelixis is downgraded from Strong Buy to Hold due to lowered 2026 revenue guidance and mixed clinical trial outcomes. Read more on EXEL stock here.

ALAMEDA, Calif., September 01, 2026--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in September:

Exelixis (EXEL) said Monday that the US Court of Appeals for the Federal Circuit has affirmed a key

ALAMEDA, Calif., August 31, 2026--Exelixis, Inc. (Nasdaq: EXEL) today announced that in the lawsuit Exelixis, Inc. (Exelixis) vs. MSN Laboratories Private Limited et al. (MSN), Civil Action No. 22-00228 (Consolidated), the U.S. Court of Appeals for the Federal Circuit (Appeal No. 25-1236) has affirmed a key portion of the 2024 judgment of the U.S. District Court for the District of Delaware in Exelixis’ favor. The appellate court upheld the District Court's decision that three patents covering t

Exelixis, Inc. (EXEL) shares enjoying institutional support – up 43.5% in a year.

A buyback funded by one oncology drug is concentrating each holder's claim while the next franchise waits on a regulatory decision.

Detailed price information for Exelixis Inc (EXEL-Q) from The Globe and Mail including charting and trades.

The drugmaker came up with a mixed second-quarter report and outlook cut.

Exelixis beats EPS estimates but misses on revenues; cuts 2026 outlook as a slower-than-expected NET launch weighs on expectations.

Exelixis (NASDAQ:EXEL) reported second-quarter 2026 revenue of approximately $629 million, including $573 million in cabozantinib franchise net product revenue, as the company prepared for a potential late-year launch of zanzalintinib in colorectal cancer and advanced a broader development program f

While the top- and bottom-line numbers for Exelixis (EXEL) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Exelixis (EXEL) delivered earnings and revenue surprises of +5.81% and -0.99%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Exelixis (EXEL) reported Q2 adjusted earnings late Wednesday of $0.91 per diluted share, up from $0.